Systematic optimization of multiplex zymography protocol to detect active cathepsins K, L, S, and v in healthy and diseased tissue: Compromise among limits of detection, reduced time, and resources

Molecular Biotechnology

Volumn 54, Issue 3, 2013, Pages 1038-1047

  Dumas, Jerald E ^a   Platt, Manu O ^a  

^a GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Cancer; Cathepsins; Cysteine protease; Detection; Zymography

Indexed keywords

CANCER; CATHEPSINS; CYSTEINE PROTEASE; DENSITOMETRIC ANALYSIS; PROTEOLYTIC ACTIVITIES; QUANTITATIVE INFORMATION; SYSTEMATIC OPTIMIZATION; ZYMOGRAPHY;

AMINO ACIDS; ASSAYS; DISEASES; ELECTROPHORESIS; ENZYME ACTIVITY; ERROR DETECTION; MULTIPLEXING; OPTIMIZATION; TISSUE;

COST BENEFIT ANALYSIS;

CATHEPSIN K; CATHEPSIN L; CATHEPSIN S; CATHEPSIN V;

ARTICLE; CAMERA; CANCER TISSUE; CONTROLLED STUDY; DENSITOMETRY; ELECTROPHORESIS; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME MODIFICATION; HUMAN; HUMAN TISSUE; IMAGE RETRIEVAL; INCUBATION TIME; LIMIT OF DETECTION; LUNG CANCER; LUNG PARENCHYMA; MOBILE PHONE; TISSUE DISTRIBUTION; ZYMOGRAPHY;

CATHEPSINS; CELLULAR PHONE; DENSITOMETRY; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HISTOLOGICAL TECHNIQUES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LIMIT OF DETECTION; LUNG; NEOPLASMS; PHOTOGRAPHY; TIME FACTORS;

EID: 84882814705     PISSN: 10736085     EISSN: 15590305     Source Type: Journal    
DOI: 10.1007/s12033-013-9658-4     Document Type: Article

References (30)

1. Chapman, H. A.; Riese, R. J.; Shi, G. P. (1997). Emerging roles for cysteine proteases in human biology. Annual Review of Physiology, 59, 63-88.
2. Sukhova, G. K.; Zhang, Y.; Pan, J. H.; Wada, Y.; Yamamoto, T.; Naito, M.; et al. (2003). Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice. The Journal Clinical Investigation, 111(6), 897-906.
3. Lecaille, F.; Bromme, D.; Lalmanach, G. (2008). Biochemical properties and regulation of cathepsin K activity. Biochimie, 90(2), 208-226.
4. Lutgens, E.; Lutgens, S. P.; Faber, B. C.; Heeneman, S.; Gijbels, M. M.; de Winther, M. P.; et al. (2006). Disruption of the cathepsin K gene reduces atherosclerosis progression and induces plaque fibrosis but accelerates macrophage foam cell formation. Circulation, 113(1), 98-107.
5. Platt, M. O.; Ankeny, R. F.; Shi, G. P.; Weiss, D.; Vega, J. D.; Taylor, W. R.; et al. (2007). Expression of cathepsin K is regulated by shear stress in cultured endothelial cells and is increased in endothelium in human atherosclerosis. American Journal of Physiology. Heart and Circulatory Physiology, 292(3), H1479-H1486.
6. Littlewood-Evans, A. J.; Bilbe, G.; Bowler, W. B.; Farley, D.; Wlodarski, B.; Kokubo, T.; et al. (1997). The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Research, 57(23), 5386-5390.
7. Lafarge, J. C.; Naour, N.; Clement, K.; Guerre-Millo, M. (2010). Cathepsins and cystatin C in atherosclerosis and obesity. Biochimie, 92(11), 1580-1586. doi: 10.1016/j.biochi.2010.04.011.
8. Platt, M. O.; Ankeny, R. F.; Jo, H. (2006). Laminar shear stress inhibits cathepsin L activity in endothelial cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 26(8), 1784-1790.
9. Sukhova, G. K.; Shi, G. P.; Simon, D. I.; Chapman, H. A.; Libby, P. (1998). Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. The Journal of Clinical Investigation, 102(3), 576-583.
10. Shi, G. P.; Sukhova, G. K.; Grubb, A.; Ducharme, A.; Rhode, L. H.; Lee, R. T.; et al. (1999). Cystatin C deficiency in human atherosclerosis and aortic aneurysms. The Journal of Clinical Investigation, 104(9), 1191-1197.
11. Hansen, L.; Parker, I.; Sutliff, R. L.; Platt, M. O.; Gleason, R. L.; Jr. (2012). Endothelial dysfunction, arterial stiffening, and intima-media thickening in large arteries from HIV-1 transgenic mice. Annals of Biomedical Engineering, 22, 22.
12. Pang, M.; Martinez, A. F.; Fernandez, I.; Balkan, W.; Troen, B. R. (2007). AP-1 stimulates the cathepsin K promoter in RAW 264.7 cells. Gene, 403(1-2), 151-158.
13. Yasuda, Y.; Li, Z.; Greenbaum, D.; Bogyo, M.; Weber, E.; Bromme, D. (2004). Cathepsin V, a novel and potent elastolytic activity expressed in activated macrophages. Journal of Biological Chemistry, 279(35), 36761-36770.
14. Park, K. Y.; Li, W. A.; Platt, M. O. (2012). Patient specific proteolytic activity of monocyte-derived macrophages and osteoclasts predicted with temporal kinase activation states during differentiation. Integrative Biology: Quantitative Biosciences from Nano to Macro, 4(12), 1459-1469.
15. Tournu, C.; Obled, A.; Roux, M. P.; Deval, C.; Ferrara, M.; Bechet, D. M. (1998). Glucose controls cathepsin expression in Ras-transformed fibroblasts. Archives of Biochemistry and Biophysics, 360(1), 15-24.
16. Mohamed, M. M.; Sloane, B. F. (2006). Cysteine cathepsins: Multifunctional enzymes in cancer. Nature Reviews Cancer, 6(10), 764-775.
17. Brubaker, K. D.; Vessella, R. L.; True, L. D.; Thomas, R.; Corey, E. (2003). Cathepsin K mRNA and protein expression in prostate cancer progression. Journal of Bone and Mineral Research, 18(2), 222-230.
18. Vasiljeva, O.; Reinheckel, T.; Peters, C.; Turk, D.; Turk, V.; Turk, B. (2007). Emerging roles of cysteine cathepsins in disease and their potential as drug targets. Current Pharmaceutical Design, 13(4), 387-403.
19. Wijkmans, J.; Gossen, J. (2011). Inhibitors of cathepsin K: A patent review (2004-2010). Expert Opinion on Therapeutic Patents, 21(10), 1611-1629.
20. Bromme, D.; Lecaille, F. (2009). Cathepsin K inhibitors for osteoporosis and potential off-target effects. Expert Opinion on Investigational Drugs, 18(5), 585-600.
21. Palermo, C.; Joyce, J. A. (2008). Cysteine cathepsin proteases as pharmacological targets in cancer. Trends in Pharmacological Sciences, 29(1), 22-28.
22. Blum, G.; Mullins, S. R.; Keren, K.; Fonovic, M.; Jedeszko, C.; Rice, M. J.; et al. (2005). Dynamic imaging of protease activity with fluorescently quenched activity-based probes. Nature Chemical Biology, 1(4), 203-209.
23. Joyce, J. A.; Baruch, A.; Chehade, K.; Meyer-Morse, N.; Giraudo, E.; Tsai, F. Y.; et al. (2004). Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell, 5(5), 443-453.
24. Li, W. A.; Barry, Z. T.; Cohen, J. D.; Wilder, C. L.; Deeds, R. J.; Keegan, P. M.; et al. (2010). Detection of femtomole quantities of mature cathepsin K with zymography. Analytical Biochemistry, 401(1), 91-98.
25. Chen, B.; Platt, M. O. (2011). Multiplex zymography captures stage-specific activity profiles of cathepsins K, L, and S in human breast, lung, and cervical cancer. Journal of Translational Medicine, 9, 109.
26. Wilder, C. L.; Park, K. Y.; Keegan, P. M.; Platt, M. O. (2011). Manipulating substrate and pH in zymography protocols selectively distinguishes cathepsins K, L, S, and V activity in cells and tissues. Archives of Biochemistry and Biophysics, 516(1), 52-57.
27. Edge, S. B.; Compton, C. C. (2010). The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Annals of Surgical Oncology, 17(6), 1471-1474.
28. Keegan, P. M.; Wilder, C. L.; Platt, M. O. (2012). Tumor necrosis factor alpha stimulates cathepsin K and V activity via juxtacrine monocyte-endothelial cell signaling and JNK activation. Molecular and Cellular Biochemistry, 367(1-2), 65-72. doi: 10.1007/s11010-012-1320-0.
29. Barry, Z. T.; Platt, M. O. (2012). Cathepsin S cannibalism of cathepsin K as a mechanism to reduce type I collagen degradation. Journal of Biological Chemistry, 287(33), 27723-27730. doi: 10.1074/jbc.M111.332684.
30. Gallagher, S.R. (2001). One-dimensional SDS gel electrophoresis of proteins. Current Protocols in Protein Science. doi: 10.1002/0471140864. ps1001s00.